Therapeutic effects and molecular mechanisms of isorhamnetin against pulmonary diseases.

Siyuan Jing, He Meng, Chunling Dong, Bo Li

Abstract readReview

In one paragraph

Review in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Siyuan Jing *Department of Pulmonary and Critical Care Medicine, Second Hospital, Jilin University, Changchun, 130041, China.

He Meng *Changchun Medical College, Changchun, 130031, China.

Chunling DongDepartment of Pulmonary and Critical Care Medicine, Second Hospital, Jilin University, Changchun, 130041, China. cldong@jlu.edu.cn.

Bo LiDepartment of Oral Anatomy and Physiology, Jilin Provincial Key Laboratory of Oral Biomedical Engineering, Hospital of Stomatology, Jilin University, Changchun, 130021, China. lbo@jlu.edu.cn.

Funding

Department of Science and Technology of Jilin Province 20220303001SF

6 · The paper itself

Abstract

Pulmonary diseases are still a serious threat to human health today, particularly in light of the recent rise of novel viruses such as SARS, influenza A, and COVID-19, which have made the situation even more dire by worsening the disease's effects on global public health. Isorhamnetin (ISO), as the active component of many medicinal plants and preparations, exhibits good antiviral, anti-inflammatory, antioxidant, and anti-tumor effects. ISO has been proven to have both preventive and treatment efficacy against pulmonary diseases. This review summarizes the effects of ISO in different pulmonary diseases, including COVID-19, pneumonia, acute lung injury/acute respiratory distress syndrome, lung cancer, asthma, pulmonary arterial hypertension, and pulmonary fibrosis, highlighting its specific molecular mechanisms against various pulmonary diseases, which is helpful for providing new perspectives on the preclinical trial and clinical application of ISO.

Indexed as

Lung DiseasesQuercetinAnimalsAnti-Inflammatory AgentsAntiviral AgentsCOVID-19COVID-19 Drug TreatmentHumans3-methylquercetinAnti-Inflammatory AgentsAntiviral AgentsQuercetinDrug treatmentIsorhamnetinMolecular mechanismsPulmonary diseasesTherapeutic effects

Identifiers

PMID41324846

DOI10.1016/j.micpath.2023.106382

What Socratic holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.